Backed by a biotech legend, two young entrepreneurs tackle one of the Holy Grails of R&D
It’s not often that two recent college grads can come up with enough cash and connections to run a Phase II study of a new …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
